Compare Arko Corp. (ARKO) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs BioNTech SE - ADR — how do they compare? Arko Corp. trades at $4.57 (market cap $493.06M), while BioNTech SE - ADR trades at $93.13 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 47.3× Arko Corp.'s market cap, and Arko Corp. pays a 2.73% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ARKO | BNTX | |
|---|---|---|
Market Cap | $493.06M | $23.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $119.34 |
52-Week Low | $3.82 | $83.89 |
Enterprise Value | $2.67B | $6.60B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.45, down 5.32% amid weak Q2 2026 earnings that missed estimates. The stock is in a bearish technical trend with key support at $4. Revenue has declined from $9.4B in 2023 to $7.6B in 2025, though net income margins remain thin at 0.19%. Recent news highlights pressure from softer retail demand and elevated fuel costs, despite management maintaining full-year EBITDA guidance.
The outlook is cautious with 100% hold ratings from analysts, reflecting concerns over margin compression and volatile consumer spending. Risks include high debt levels and competitive pressures, but the company's consistent dividend payments and positive operating cash flow offer some stability. Further price movement hinges on execution against guidance and macroeconomic conditions.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
